Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis.

被引：0
|
作者：
van Herwaarden, Noortje [1 ]
van der Maas, Aatke [1 ]
Minten, Michiel [1 ]
van den Hoogen, Frank H. J. [2 ,3 ]
van Vollenhoven, Ronald F. [4 ]
Bijlsma, Johannes W. J. [5 ]
van den Bemt, Bart [1 ]
den Broeder, Alfons A. [1 ]
机构：
[1] Sint Maartensklin, Nijmegen, Netherlands
[2] Sint Maartensklin, Rheumatol Ctr, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[4] Karolinska Inst, Unit Clin Therapy Res ClinTrid, Stockholm, Sweden
[5] Univ Med Ctr Utrecht, Utrecht, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1843
引用
收藏
页码：S810 / S811
页数：2
相关论文
共 50 条
  • [1] Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
    van Herwaarden, Noortje
    van der Maas, Aatke
    Minten, Michiel J. M.
    van den Hoogen, Frank H. J.
    Kievit, Wietske
    van Vollenhoven, Ronald F.
    Bijlsma, Johannes W. J.
    van den Bemt, Bart J. F.
    den Broeder, Alfons A.
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [2] Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
    Rosalía Martínez-Pérez
    Sergio Rodríguez-Montero
    Alejandro Muñoz
    Julia Uceda
    Mario León
    Francisco Gallo
    Maria Luisa Velloso
    José Luis Marenco
    Journal of Translational Medicine, 9 (Suppl 2)
  • [3] Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
    Michielsens, Celia A. J.
    den Broeder, Nathan
    van den Hoogen, Frank H. J.
    Mahler, Elien A. M.
    Teerenstra, Steven
    van der Heijde, Desiree
    Verhoef, Lise M.
    den Broeder, Alfons A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (10) : 1392 - 1399
  • [4] Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial
    Mariette, Xavier
    Rouanet, Stephanie
    Sibilia, Jean
    Combe, Bernard
    Le Loet, Xavier
    Tebib, Jacques
    Jourdan, Rosemary
    Dougados, Maxime
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (08) : 1508 - 1514
  • [5] Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial
    l'Ami, Merel J.
    Krieckaert, Charlotte L. M.
    Nurmohamed, Michael T.
    van Vollenhoven, Ronald F.
    Rispens, Theo
    Boers, Maarten
    Wolbink, Gerrit Jan
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 484 - 487
  • [6] ULTRA-LOW DOSES OF RITUXIMAB OR RETREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL
    Verhoef, L. M.
    den Broeder, Nathan
    Thurlings, R. M.
    van der Laan, W. H.
    van der Weele, W.
    Kok, Marc
    Moens, H. J. Bernelot
    Woodworth, Thasia
    van den Bemt, Bart
    van den Hoogen, Frank
    den Broeder, Alfons
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 264 - 265
  • [7] A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years
    Jobanputra, Paresh
    Maggs, Fiona
    Deeming, Alison
    Carruthers, David
    Rankin, Elizabeth
    Jordan, Alison C.
    Faizal, Abdul
    Goddard, Carolyn
    Pugh, Mark
    Bowman, Simon J.
    Brailsford, Sue
    Nightingale, Peter
    BMJ OPEN, 2012, 2 (06):
  • [8] Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
    Smolen, Josef S.
    Nash, Peter
    Durez, Patrick
    Hall, Stephen
    Ilivanova, Elena
    Irazoque-Palazuelos, Fedra
    Miranda, Pedro
    Park, Min-Chan
    Pavelka, Karel
    Pedersen, Ronald
    Szumski, Annette
    Hammond, Constance
    Koenig, Andrew S.
    Vlahos, Bonnie
    LANCET, 2013, 381 (9870): : 918 - 929
  • [9] Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial
    Tamai, Hiroya
    Ikeda, Kei
    Miyamoto, Toshiaki
    Taguchi, Hiroaki
    Kuo, Chang-Fu
    Shin, Kichul
    Hirata, Shintaro
    Okano, Yutaka
    Sato, Shinji
    Yasuoka, Hidekata
    Kuwana, Masataka
    Ishii, Tomonori
    Kameda, Hideto
    Kojima, Toshihisa
    Taninaga, Takehiro
    Mori, Masahiko
    Miyagishi, Hideaki
    Sato, Yasunori
    Tsai, Wen-Chan
    Takeuchi, Tsutomu
    Kaneko, Yuko
    LANCET RHEUMATOLOGY, 2023, 5 (04): : 215 - 224
  • [10] Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial
    Verhoeff, Lise M.
    den Broeder, Nathan
    Thurlings, Rogier M.
    van der Laan, Willemijn H.
    van der Weele, Wilfred
    Kok, Marc R.
    Moens, Hein J. Bernelot
    Woodworth, Thasia G.
    van den Bemt, Bart J. F.
    van den Hoogen, Frank H. J.
    den Broeder, Alfons A.
    LANCET RHEUMATOLOGY, 2019, 1 (03): : E145 - E153
12345